-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the World Health Organization issued a temporary guideline for mashup vaccination of the new crown vaccine based on existing research data
.
It emphasized that the first choice for vaccination is to use vaccines produced by the same manufacturer; as more research data is released, it is not ruled out to adjust the "mixed" guidelines
Apply to WHO
Emergency use of all new coronavirus vaccines on the list
This guide is based on the recommendations recently made by the WHO Strategic Advisory Panel and applies to all the new crown vaccines on the WHO emergency use list
.
The guidelines suggest that if the first dose is a viral vector vaccine, the messenger ribonucleic acid (mRNA) vaccine can be vaccinated afterwards, regardless of whether it is the second dose or the booster dose; and vice versa
WHO said that based on the safety of vaccines, immune force and efficacy data, the standard practice is to use the same manufacturers throughout the vaccine
.
However, considering the availability of vaccines, vaccines produced by different manufacturers can be used flexibly
WHO will re-evaluate the advantages and risks of "smashing"
According to the provisional guidelines, existing research mainly involves the impact of "mixed fighting" on human immunity, and data on safety is limited.
The data on "mixed fighting" of inactivated vaccines needs to be further supplemented
.
As the research deepens, the WHO will reassess the advantages and risks of "smashing"
As of December 7, the new crown vaccines that have entered the WHO emergency use list include China's Coxing vaccine and Sinopharm vaccine, India's native vaccine Covaxin, American Johnson & Johnson vaccine, British AstraZeneca vaccine, American Modena vaccine and Pfizer vaccine
.
Among them, the first three are inactivated vaccines, the fourth and fifth are adenovirus vector vaccines, and the latter two are mRNA vaccines
According to Reuters, in order to cope with the soaring number of new crown infections , insufficient vaccine supply, and slow progress in vaccination, some countries and regions have begun "mixing" vaccines
.
Recently, the World Health Organization issued a temporary guideline for mashup vaccination of the new crown vaccine based on existing research data
.
It emphasized that the first choice for vaccination is to use vaccines produced by the same manufacturer; as more research data is released, it is not ruled out to adjust the "mixed" guidelines
guide
Apply to WHO
Apply to WHOEmergency use of all new coronavirus vaccines on the list
Emergency use of all new coronavirus vaccines on the listThis guide is based on the recommendations recently made by the WHO Strategic Advisory Panel and applies to all the new crown vaccines on the WHO emergency use list
.
The guidelines suggest that if the first dose is a viral vector vaccine, the messenger ribonucleic acid (mRNA) vaccine can be vaccinated afterwards, regardless of whether it is the second dose or the booster dose; and vice versa
The guidelines suggest that if the first dose is a viral vector vaccine, the messenger ribonucleic acid (mRNA) vaccine can be vaccinated afterwards, regardless of whether it is the second dose or the booster dose; and vice versa
WHO said that based on the safety of vaccines, immune force and efficacy data, the standard practice is to use the same manufacturers throughout the vaccine
.
However, considering the availability of vaccines, vaccines produced by different manufacturers can be used flexibly
.
Only by "seriously considering the supply of vaccines" and "potential advantages and risks of specific products" and other factors can "mixing" be carried out
.
WHO recognizes the entire vaccination completed by "smashing"
.
Immunization WHO recognizes the complete vaccination completed by "smashing"
.
WHO recognizes the entire vaccination completed by "smashing"
.
WHO will re-evaluate the advantages and risks of "smashing"
WHO will re-evaluate the advantages and risks of "smashing"According to the provisional guidelines, existing research mainly involves the impact of "mixed fighting" on human immunity, and data on safety is limited.
The data on "mixed fighting" of inactivated vaccines needs to be further supplemented
.
As the research deepens, the WHO will reassess the advantages and risks of "smashing"
.
As of December 7, the new crown vaccines that have entered the WHO emergency use list include China's Coxing vaccine and Sinopharm vaccine, India's native vaccine Covaxin, American Johnson & Johnson vaccine, British AstraZeneca vaccine, American Modena vaccine and Pfizer vaccine
.
Among them, the first three are inactivated vaccines, the fourth and fifth are adenovirus vector vaccines, and the latter two are mRNA vaccines
.
According to Reuters, in order to cope with the soaring number of new crown infections , insufficient vaccine supply, and slow progress in vaccination, some countries and regions have begun "mixing" vaccines
.
